Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
CNY 3.4
(-0.58%)
CNY 3.4
(-0.58%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 654.01 Million CNY | -2.58% |
| 2022 | 608.72 Million CNY | -16.0% |
| 2021 | 768.64 Million CNY | 20.81% |
| 2020 | 632.49 Million CNY | -13.52% |
| 2019 | 734.62 Million CNY | 4.65% |
| 2018 | -825.85 Million CNY | 2.25% |
| 2017 | 699.48 Million CNY | 6.71% |
| 2016 | 471.42 Million CNY | 35.5% |
| 2015 | 480.01 Million CNY | 49.9% |
| 2014 | 323.23 Million CNY | 287.28% |
| 2013 | 84.31 Million CNY | 7.53% |
| 2012 | 76.7 Million CNY | 12.78% |
| 2011 | 66.14 Million CNY | 26.38% |
| 2010 | 55.04 Million CNY | -22.44% |
| 2009 | 61.8 Million CNY | 29.36% |
| 2008 | 48.74 Million CNY | 24.39% |
| 2007 | 44.51 Million CNY | 57.05% |
| 2006 | 28.35 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 110.79 Million CNY | -21.24% |
| 2024 Q3 | 104.16 Million CNY | -5.98% |
| 2024 Q1 | 89.6 Million CNY | 6.98% |
| 2023 Q2 | 161.35 Million CNY | 88.03% |
| 2023 Q3 | 137.68 Million CNY | -14.67% |
| 2023 FY | - CNY | -2.58% |
| 2023 Q4 | 101.67 Million CNY | -26.15% |
| 2023 Q1 | 85.81 Million CNY | 40.87% |
| 2022 Q1 | 104.19 Million CNY | -38.6% |
| 2022 FY | - CNY | -16.0% |
| 2022 Q4 | 60.91 Million CNY | -60.56% |
| 2022 Q3 | 154.45 Million CNY | 42.68% |
| 2022 Q2 | 108.24 Million CNY | 3.89% |
| 2021 Q1 | 125.11 Million CNY | -4.54% |
| 2021 Q3 | 119.38 Million CNY | -13.3% |
| 2021 Q4 | 169.71 Million CNY | 42.16% |
| 2021 FY | - CNY | 20.81% |
| 2021 Q2 | 137.69 Million CNY | 10.06% |
| 2020 Q1 | -21.91 Million CNY | -115.65% |
| 2020 Q4 | 131.06 Million CNY | -30.07% |
| 2020 FY | - CNY | -13.52% |
| 2020 Q3 | 187.41 Million CNY | 40.54% |
| 2020 Q2 | 133.34 Million CNY | 708.48% |
| 2019 Q1 | 84.04 Million CNY | 156.69% |
| 2019 Q4 | 140.05 Million CNY | -7.94% |
| 2019 Q2 | 150.33 Million CNY | 78.87% |
| 2019 Q3 | 152.13 Million CNY | 1.19% |
| 2019 FY | - CNY | 4.65% |
| 2018 Q4 | 32.74 Million CNY | -76.17% |
| 2018 Q3 | 137.41 Million CNY | -28.54% |
| 2018 Q2 | 192.3 Million CNY | 55.99% |
| 2018 FY | - CNY | 2.25% |
| 2018 Q1 | 123.28 Million CNY | -18.44% |
| 2017 Q3 | 170.94 Million CNY | 5.06% |
| 2017 Q2 | 162.71 Million CNY | 157.72% |
| 2017 FY | - CNY | 6.71% |
| 2017 Q1 | 63.13 Million CNY | -69.85% |
| 2017 Q4 | 151.15 Million CNY | -11.58% |
| 2016 FY | - CNY | 35.5% |
| 2016 Q2 | 156.77 Million CNY | 119.24% |
| 2016 Q3 | 108.52 Million CNY | -30.77% |
| 2016 Q4 | 209.4 Million CNY | 92.95% |
| 2016 Q1 | 71.5 Million CNY | -41.11% |
| 2015 FY | - CNY | 49.9% |
| 2015 Q2 | 112.16 Million CNY | 70.3% |
| 2015 Q1 | 65.86 Million CNY | -49.09% |
| 2015 Q4 | 121.42 Million CNY | 35.81% |
| 2015 Q3 | 89.4 Million CNY | -20.29% |
| 2014 Q2 | 79.65 Million CNY | 958.83% |
| 2014 Q1 | 7.52 Million CNY | -72.84% |
| 2014 Q3 | 75.29 Million CNY | -5.47% |
| 2014 FY | - CNY | 287.28% |
| 2014 Q4 | 129.36 Million CNY | 71.8% |
| 2013 Q1 | 7.82 Million CNY | -76.28% |
| 2013 Q2 | 20.68 Million CNY | 164.22% |
| 2013 Q3 | 12.26 Million CNY | -40.69% |
| 2013 Q4 | 27.69 Million CNY | 125.83% |
| 2013 FY | - CNY | 7.53% |
| 2012 FY | - CNY | 12.78% |
| 2012 Q1 | 9.36 Million CNY | -69.7% |
| 2012 Q2 | 14.84 Million CNY | 58.41% |
| 2012 Q3 | 11.93 Million CNY | -19.59% |
| 2012 Q4 | 33 Million CNY | 176.57% |
| 2011 Q3 | 11.08 Million CNY | -49.15% |
| 2011 Q2 | 21.8 Million CNY | 179.44% |
| 2011 Q1 | 7.8 Million CNY | -56.22% |
| 2011 FY | - CNY | 26.38% |
| 2011 Q4 | 30.91 Million CNY | 178.88% |
| 2010 Q1 | 8.31 Million CNY | -63.56% |
| 2010 Q2 | 19.81 Million CNY | 138.24% |
| 2010 FY | - CNY | -22.44% |
| 2010 Q4 | 17.81 Million CNY | 97.23% |
| 2010 Q3 | 9.03 Million CNY | -54.41% |
| 2009 FY | - CNY | 29.36% |
| 2009 Q1 | 7.48 Million CNY | 0.0% |
| 2009 Q2 | 17.56 Million CNY | 134.69% |
| 2009 Q4 | 22.82 Million CNY | 58.44% |
| 2009 Q3 | 14.4 Million CNY | -17.96% |
| 2008 FY | - CNY | 24.39% |
| 2007 FY | - CNY | 57.05% |
| 2006 FY | - CNY | 0.0% |